Navigation Links
BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
Date:7/28/2008

s that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manuf
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
2. BioCryst Updates Peramivir Clinical Development Plan
3. BioCryst Provides Forodesine HCl Update
4. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
5. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
6. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
7. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
8. GeoVax Reports Progress on Its AIDS Vaccine Technology
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... CHICAGO, Ill. , June 1, 2015  AbbVie ... 2015 Healthcare Conference on Thursday, June 4, 2015. ... will participate in a question and answer session at ... webcast of the presentation will be accessible through AbbVie,s ... archived edition of the session will be available later ...
(Date:6/1/2015)... BOSTON , June 1, 2015 Symbiotix ... a $2.3 million Phase 2 Small Business Technology Transfer ... (NIH) National Institute of Allergy and Infectious Diseases (NIAID). ... is developing a novel class of molecular therapeutics ... lead clinical candidate, Polysaccharide A (PSA), is the first ...
(Date:6/1/2015)... N.J. , June 1, 2015  Elusys ... and Drug Administration (FDA) has accepted for filing ... Anthim® (obiltoxaximab) for the treatment and prevention of ... submitted on March 20, 2015. Anthim is a ... Stockpile, the U.S. government,s repository of critical medical ...
Breaking Medicine Technology:Symbiotix Biotherapies Announces $2.3 Million Award from NIH's National Institute of Allergy and Infectious Diseases (NIAID) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 3
... NEW YORK, April 18, 2012 Financial executives in ... excise tax and the burden of its related compliance ... bottom lines, according to a survey conducted by KPMG ... of respondents said their companies are already contemplating actions ...
... NEW YORK, April 18, 2012 ... initiates coverage on Pacira Pharmaceuticals ... price target $18.00. ... is a member of the ...
Cached Medicine Technology:KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3
(Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into its VIP Professional Woman of the ... for leadership in safety, environment, health and emergency response. ... professional women, boasting more than 700,000 members and over ... Lourinda with this important honor,” said NAPW President Star ...
(Date:6/1/2015)... NY (PRWEB) June 02, 2015 ... Selma Tansey as a 2015-2016 inductee into ... recognized with this prestigious distinction for leadership in mental ... for professional women, boasting more than 700,000 members and ... present Selma with this important honor," said NAPW President ...
(Date:6/1/2015)... Austin, TX (PRWEB) June 01, 2015 ... LLC, to facilitate their investors IRA transactions. AdvantaIRA Trust, ... , Giving investors the ability to fund positions using ... choice to participate on a project, even if there ... 2. Provide an additional funding source for Carson and ...
(Date:6/1/2015)... Unlike most generator rental companies, which raise their rates by ... when the generator is in standby mode, WPP charges a ... or not. WPP also offers an offsite storage option — ... few hours — for companies that do not have the ... “Even minor business disruptions are very expensive for commercial and ...
(Date:6/1/2015)... Linda Kincaid, age 67, knew something was wrong. She constantly ... thought it was just a part of getting older, but ... After going to the doctor, she received a distressing diagnosis: ... might happen to her. , Linda is not alone. As ... each year. Valve disease involves damage to one or more ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Worldwide Power Products Offers “Budget Billing” Contingency Generator Rental Program; Guarantees Power for Peak of Hurricane Season and Beyond 2Health News:A New Online Resource for Those Living with Heart Valve Disease 2Health News:A New Online Resource for Those Living with Heart Valve Disease 3
... The chief executive officer of a health authority in St. ... faulty tests that may have affected the care of ... the Eastern Health Regional Authority agreed that Eastern Health could ... knew about the hormone receptor tests. ,'I regret ...
... agreed on a $5-billion initiative with major banks to retrofit ... first such enterprise to combat climate change. ,Former ... week with a summit in New York attended by mayors ... discuss climate change. ,Clinton's initiative launched on Wednesday ...
... President A.P.J. Abdul Kalam Thursday stressed on the necessity ... to increase neuro activities of mentally challenged people. ... of Manovikas Kendra, a premier rehabilitation and research institute ... going on worldwide and it will take five to ...
... offered their first insights at research on a group ... will serve as models of typical childhood development. ... Health study suggest that healthy children perform better on ... was particularly true among children from low-income families. ...
... found that chemical relaxers used to straighten hair are not ... among African-American women. ,Hair relaxers can enter the ... are not fully monitored by the Food and Drug Administration, ... study named Black Womens Health Study was conducted by a ...
... In order to makeup for the loss of the ... hospitals run by state governments , the railways and ... from them to make them profit making units. ... Hindustan Antibiotics Limited, Bengal Chemicals and Pharmaceuticals Limited, Hindustan ...
Cached Medicine News:Health News:Faulty Hormone Tests Compromised Healthcare Of Breast Cancer Patients 2Health News:World Cities Join Hands to Combat Climate Change 2Health News:Library Of Brains To Aid Study of Brain Development In Children 2Health News:Library Of Brains To Aid Study of Brain Development In Children 3Health News:Hair Relaxers Not Linked With Breast Cancer Risk 2Health News:Government Hospitals to the Rescue of Loss-making Pharma Companies 2
... SP Surgical Table combines innovation and design ... up to 1,000 lbs. You can safely ... normal and reverse orientation and have virtually ... patients.,The Amsco 3085 SP Table offers the ...
... 1st MPJ IMPLANT SYSTEM is a unique ... of the 1st metatarsal phalangeal joint resulting ... revision of a previous arthroplasty. The ... pain relief, superior function and longevity. ...
... part in our daily lives. But degenerative ... cause severe handicaps. A decisive consideration in ... to produce a reconstructed joint function that ... possible.,The cementless RM Finger System has proven ...
... important part in our daily lives. But ... can cause severe handicaps. A decisive consideration ... was to produce a reconstructed joint function ... nearly possible.,The cementless RM Finger System has ...
Medicine Products: